Therapeutic Asset Ratings
136 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
L-Nmma
HER2-negative Breast Cancer
The Methodist Hospital Research Institute
P2
CCC
(48)
Mitoxantrone
HER2-negative Breast Cancer
Fudan University
P2
CCC
(48)
N-DESMETHYL-4-HYDROXYTAMOXIFEN
HER2-negative Breast Cancer
Atossa Therapeutics, Inc.
P2
CCC
(48)
Neratinib
HER2-negative Breast Cancer
Massachusetts General Hospital
P2
CCC
(48)
PCS6422
HER2-negative Breast Cancer
Processa Pharmaceuticals
P2
CCC
(48)
Pexidartinib
HER2-negative Breast Cancer
QuantumLeap Healthcare Collaborative
P2
CCC
(48)
PIFLUFOLASTAT
HER2-negative Breast Cancer
University of Wisconsin, Madison
P2
CCC
(48)
Pyrotinib
HER2-negative Breast Cancer
Fudan University
P2
CCC
(48)
Rilvegostomig
HER2-negative Breast Cancer
QuantumLeap Healthcare Collaborative
P2
CCC
(48)
Sacituzumab Tirumotecan
HER2-negative Breast Cancer
Fudan University
P2
CCC
(48)
Sarilumab
HER2-negative Breast Cancer
QuantumLeap Healthcare Collaborative
P2
CCC
(48)
Shr-1167
HER2-negative Breast Cancer
Fudan University
P2
CCC
(48)
Shr-4602
HER2-negative Breast Cancer
Fudan University
P2
CCC
(48)
Shr-6209
HER2-negative Breast Cancer
Fudan University
P2
CCC
(48)
Shr-A1811
HER2-negative Breast Cancer
Fudan University
P2
CCC
(48)
Shr-A1921
HER2-negative Breast Cancer
Fudan University
P2
CCC
(48)
Shr-A2009
HER2-negative Breast Cancer
Fudan University
P2
CCC
(48)
Shr-A2102
HER2-negative Breast Cancer
Fudan University
P2
CCC
(48)
Sorafenib
HER2-negative Breast Cancer
Fudan University
P2
CCC
(48)
Toripalimab
HER2-negative Breast Cancer
Zhejiang Cancer Hospital
P2
CCC
(48)
tqb2102
HER2-negative Breast Cancer
Fudan University
P2
CCC
(48)
tqb2868
HER2-negative Breast Cancer
Fudan University
P2
CCC
(48)
Trastuzumab Duocarmazine
HER2-negative Breast Cancer
QuantumLeap Healthcare Collaborative
P2
CCC
(48)
Trebananib
HER2-negative Breast Cancer
QuantumLeap Healthcare Collaborative
P2
CCC
(48)
Trilaciclib
HER2-negative Breast Cancer
QuantumLeap Healthcare Collaborative
P2
CCC
(48)
Showing 76 to 100 of 136 assets
Previous
Page 4 of 6
Next